Simple Summary CD3-bispecific antibody therapy is a form of immunotherapy that enables
soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is …

Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the US,
claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the …

Therapeutic approaches are needed to promote T cell–mediated destruction of poorly
immunogenic,“cold” tumors typically associated with minimal response to immune …

Highlights•T cell redirection is the most promising immunotherapeutic modality for cancer
treatment.•Many parameters for optimal activity of T cell-recruiting BsAb and of CAR T are …

With the development of molecular cloning technology and the deep understanding of
antibody engineering, there are diverse bispecific antibody formats from which to choose to …

Over the last decade, the development of multiple strategies to allow the safe transfer from
the donor to the patient of high numbers of partially HLA-incompatible T cells has …

Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a
subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to …

Since their discovery, antibodies have been viewed as ideal candidates or “magic bullets”
for use in targeted therapy in the fields of cancer, autoimmunity, and chronic inflammatory …

A bottleneck for immunotherapy of cancer is the immunosuppressive microenvironment in
which the tumor cells are located. Regardless of the fact that large numbers of tumor-specific …

Purpose: A phase II study was conducted to evaluate the safety and efficacy of the
combination of HER2 bispecific antibody (HER2Bi)-armed activated T cells (HER2 BAT) and …